Skjetten, Norway
Sarepta Offshore Inc is focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. The company is a global biotechnology firm dedicated to engineering precision genetic medicine to address rare diseases. Sarepta aims to shorten the time from lab to patient, build the world’s largest gene therapy manufacturing capacity, and rethink access and reimbursement models for revolutionary new treatments. The company has FDA-approved treatments for Duchenne Muscular Dystrophy and other rare diseases. Sarepta was founded in 2026 and is headquartered in Norway. The company has a strong commitment to following the science and continuously evaluating other diseases and modalities to pursue.
Browsing, company names, locations and sectors are always free. A free account adds 5 contact releases every month — e-mail and phone, view or export. Need more? Contact packs start at 19 € for 50, or upgrade to a monthly plan.
Yes — no card required. Browsing is always free, and a free account adds 5 contact releases every month.
Your first 5 contact releases each month are included in the free account. After that, packs start at 19 € for 50 contacts (view or export), or a monthly plan for regular use.
Companies are harvested from the open web — registers, websites and industry directories — not self-registered sign-ups. Contact details are shown only once you use a release or credit, never invented.